whatshot

GNFT   $4.19  -1.41% Market Closed After Close 4.22 0.72%

Genfit SA
show_chart Advanced Chart of GNFT
Last Events:

2023-08-09 Trend pattern changed from расширяющаяся формация to нисходящий клин.

2023-08-09 Signal in Stochastic changed from bullish reversal to bullish. The stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: up-crossing the middle level.

2023-08-09 Signal in MACD changed from bearish recovery to bearish weakening. Oscillator MACD is in the negative territory it's lower than the signal line and grows. These factors mean that the falling trend persists, but the growth rate is declining. Last signal: entry into the oversold zone.

2023-08-06 Trend pattern changed from расходящийся треугольник to расширяющаяся формация.

2023-08-06 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-08-05 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-05 Trend Power changed from slow to almost flat.

2023-08-05 Trend changed from turning up to down and flat.

Current temperature: 3.29
ST: 0, Cor:

Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy Buy None
rsi None ActivelyBuy ActivelyBuy
macd None None None
stoch None None None
ma20 Sell None ActivelyBuy
ma50 None None None
ma100 Buy Buy Sell
Candlestick PatternSept. 11, 2024 Bullish Ladder - is a made up of five candlesticks. Pattern appears on a downtrend. Three strong black candlesticks follows by the fourth black candlestick closes also lower but has a long upper shadow. The fifth day is a strong white with an open above the previous day’s body. Considered to be a bullish reversal pattern.
ISIN US3722791098
Website https://www.genfit.com
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.